John Allan, MD, Weill Cornell Medicine, New York, NY, outlines the results of a pooled analysis of four clinical trials investigating the long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukemia (CLL) with a four-year follow-up of patients with TP53 aberrations. The clinical trials included in the analysis were PCYC-1122e (NCT01500733), PCYC-1130 (NCT02264574), E1912 (NCT02048813) and RESONATE-2 (NCT01722487). The analysis found that first-line ibrutinib-based treatment resulted in sustained efficacy with high progression-free survival (PFS) and overall survival (OS) rates in CLL patients with TP53 aberrations. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
John Allan, MD, has done consultancy work, participated in advisory boards and/or received honoraria from Pharmacyclics, Janssen, Abbvie, BeiGene, Genentech and AstraZeneca; and has received research Funding from Genentech, Janssen and TG Therapeutics.